News Releases

Date	Title and Summary	View
Aug 05, 2020	Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine Company working to ensure broad global access to COVID-19 vaccine candidate, following approval from regulators NEW BRUNSWICK, N.J., Aug. 5, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with
Aug 03, 2020	Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior
Jul 30, 2020	U.S. Food and Drug Administration Approves STELARA® (ustekinumab) for Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Jul 30, 2020	Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies Study published in Nature shows J&J's investigational SARS-CoV-2 vaccine elicits a strong immune response that protects against subsequent infection First-in-human Phase 1/2a clinical trial now underway in United States and Belgium; Phase 3 clinical trial expected to commence in September NEW
Jul 20, 2020	Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2020 NEW BRUNSWICK, N.J. , July 20, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2020 of $1.01 per share on the company's common stock. The dividend is payable on September 8, 2020 to shareholders of
Jul 17, 2020	Johnson & Johnson to Participate in Citi ‘Of Hearts and Minds’ Conference Call Series
Jul 17, 2020	Interim Six-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosa
Jul 16, 2020	Johnson & Johnson Reports 2020 Second-Quarter Results: - Sales of $18.3 billion reflecting a decline of 10.8%, operational decline of 9.0%* and adjusted operational decline of 8.8%, primarily driven by the negative impact of the COVID-19 pandemic - EPS of $1.36 decreased 34.6%; adjusted EPS of $1.67 decreased 35.3%; 2019 included gain from sale of
Jul 14, 2020	TREMFYA® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
Jul 06, 2020	Stop TB Partnership and Johnson & Johnson, with support from USAID and The Global Fund, Announce Price Reduction for SIRTURO® (bedaquiline) for Treatment of Drug-Resistant Tuberculosis in Low- and Middle-Income Countries